Yasunaga Yoshikawa
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Yasunaga Yoshikawa has a total of 84 co-authors. Here are the top co-authors by number of shared publications:
Koichi Orino
Laboratory of Veterinary Biochemistry, School of Veterinary Medicine, Kitasato University, Higashi23-35-1, Towada, 034-8628, Aomori, Japan
9 shared publications- Koichi Orino
School of Veterinary Medicine, Kitasato University
6 shared publications Masami Morimatsu
Laboratory of Laboratory Animal Science and Medicine, Department of Disease Control, Graduate School of Veterinary Medicine, Hokkaido University, Sapporo, 060- 0818, Japan
6 shared publications- Kazuhiko Ochiai
School of Veterinary Nursing and Technology, Faculty of Veterinary Science, Nippon Veterinary and Life Science University, Tokyo 180-8602, Japan
5 shared publications - Masami Morimatsu
Laboratory of Laboratory Animal Science and Medicine, Graduate School of Veterinary Medicine, Hokkaido University, Sapporo 060-0818, Japan
5 shared publications Taisuke Kitano
Laboratory of Veterinary Biochemistry, School of Veterinary Medicine, Kitasato University, Higashi23-35-1, Towada, 034-8628, Aomori, Japan
4 shared publications
Latest Publications
- 30 June 2026
- Published by Springer Nature in Molecular Biology Reports
- Vol. 53  (1)
Overexpression of the BRC repeat 8 of BRCA2 hyperstabilizes RAD51 and alters DNA repair dynamics
RAD51 plays an essential role in maintaining genomic stability via homologous recombination (HR). Aberrant RAD51 expression compromises genomic integrity and influences cellular responses to DNA-damaging agents. RAD51 expression is tightly regulated in normal cells, and its increased expression is associated with therapeutic resistance and poor prognosis in various cancers. BRCA2, a tumor suppressor gene product, promotes HR by directly interacting with RAD51 via eight evolutionarily conserved BRC repeats (BRC1-8). Individual BRC repeats share relatively low sequence similarity and possess distinct biochemical properties. We previously reported that the expression of certain BRC repeat peptides alters RAD51 protein levels, suggesting that individual BRC repeats distinctly affect RAD51 expression. We aimed to identify the specific BRC repeat regions affecting RAD51 protein levels. Notably, BRC8 expression significantly elevated RAD51 protein levels and foci formation, possibly by inhibiting its ubiquitin-mediated degradation. Paradoxically, despite increased RAD51 foci formation, BRC8 expression significantly reduced HR repair efficiency and increased sensitivity to DNA-damaging agents. Our findings suggest that BRC8 overexpression stabilizes RAD51 by inhibiting ubiquitin-dependent degradation of RAD51, leading to increased persistence of RAD51 foci, indicating impaired timely removal of RAD51 from DNA damage sites and reduced HR efficiency. Moreover, altered cell cycle distribution may contribute to reduced non-homologous end-joining efficiency, further enhancing cellular sensitivity to DNA-damaging agents. Collectively, these findings provide a basis to further explore the potential of BRC8-based peptides as tools for modulating RAD51 stability and sensitizing cells to DNA damage.
- 30 June 2026
- Published by Springer Nature in Molecular Biology Reports
- Vol. 53  (1)
Overexpression of the BRC repeat 8 of BRCA2 hyperstabilizes RAD51 and alters DNA repair dynamics
RAD51 plays an essential role in maintaining genomic stability via homologous recombination (HR). Aberrant RAD51 expression compromises genomic integrity and influences cellular responses to DNA-damaging agents. RAD51 expression is tightly regulated in normal cells, and its increased expression is associated with therapeutic resistance and poor prognosis in various cancers. BRCA2, a tumor suppressor gene product, promotes HR by directly interacting with RAD51 via eight evolutionarily conserved BRC repeats (BRC1-8). Individual BRC repeats share relatively low sequence similarity and possess distinct biochemical properties. We previously reported that the expression of certain BRC repeat peptides alters RAD51 protein levels, suggesting that individual BRC repeats distinctly affect RAD51 expression. We aimed to identify the specific BRC repeat regions affecting RAD51 protein levels. Notably, BRC8 expression significantly elevated RAD51 protein levels and foci formation, possibly by inhibiting its ubiquitin-mediated degradation. Paradoxically, despite increased RAD51 foci formation, BRC8 expression significantly reduced HR repair efficiency and increased sensitivity to DNA-damaging agents. Our findings suggest that BRC8 overexpression stabilizes RAD51 by inhibiting ubiquitin-dependent degradation of RAD51, leading to increased persistence of RAD51 foci, indicating impaired timely removal of RAD51 from DNA damage sites and reduced HR efficiency. Moreover, altered cell cycle distribution may contribute to reduced non-homologous end-joining efficiency, further enhancing cellular sensitivity to DNA-damaging agents. Collectively, these findings provide a basis to further explore the potential of BRC8-based peptides as tools for modulating RAD51 stability and sensitizing cells to DNA damage.
- Open Access
- 17 October 2025
- Published by Frontiers Media SA in Frontiers in Veterinary Science
- Vol. 12, 1702872
Editorial: Cancer in domestic, exotic and wild animals: new horizons in tumorigenesis, diagnosis, prognosis and therapeutics through comparative oncology
Pandas ( Ailuropoda melanoleuca ), Roe deer ( Capreolus capreolus), human, One Health Significant advances in understanding cancer biology have been made in recent years, leading to increasingly accurate and early diagnosis and specific and effective therapeutic treatments. Advances in the identification of increasingly sophisticated prognostic markers have enabled veterinarians to predict the course of many neoplastic diseases, improving the quality of clinical and therapeutic approaches and the rate of recovery for many animals affected by cancer. Supporting these scientific advances and the fundamental and exciting findings of recent years, biomolecular and comparative studies have also been conducted across multiple animal species, including humans. These studies have allowed for the biological and genetic characterization of numerous tumors, further strengthening the importance of scientific approaches aimed at a "One Health" assessment. The comparative study of cancer in different animal species, including domestic, exotic, and wild animals, can provide valuable information of various types and degrees, with considerable potential for improving diagnostic, prognostic, and therapeutic approaches. Recent studies have shown that even particularly tumor-resistant animals, such as naked mole rats, blind mole rats, elephants, and whales, have attracted increasing attention from researchers, with the aim of characterizing the most intimate mechanisms of disease resistance in these species and breeds (1). These cancer resistance mechanisms observed in these species could offer new strategic approaches for anticancer treatments in humans, as well as in domestic and exotic animals. Therefore, by examining both tumor-prone animals closest to humans, such as dogs and cats, and tumor-resistant species, comparative oncology explores the similarities and differences between human and animal cancers, contributing to the development of new diagnostic tools, therapies, and preventive strategies that advance both human and veterinary medicine.
- 17 October 2025
- Published by Frontiers Media SA in Frontiers in Veterinary Science
- Vol. 12, 1702872
Open AccessEditorial: Cancer in domestic, exotic and wild animals: new horizons in tumorigenesis, diagnosis, prognosis and therapeutics through comparative oncology
Pandas ( Ailuropoda melanoleuca ), Roe deer ( Capreolus capreolus), human, One Health Significant advances in understanding cancer biology have been made in recent years, leading to increasingly accurate and early diagnosis and specific and effective therapeutic treatments. Advances in the identification of increasingly sophisticated prognostic markers have enabled veterinarians to predict the course of many neoplastic diseases, improving the quality of clinical and therapeutic approaches and the rate of recovery for many animals affected by cancer. Supporting these scientific advances and the fundamental and exciting findings of recent years, biomolecular and comparative studies have also been conducted across multiple animal species, including humans. These studies have allowed for the biological and genetic characterization of numerous tumors, further strengthening the importance of scientific approaches aimed at a "One Health" assessment. The comparative study of cancer in different animal species, including domestic, exotic, and wild animals, can provide valuable information of various types and degrees, with considerable potential for improving diagnostic, prognostic, and therapeutic approaches. Recent studies have shown that even particularly tumor-resistant animals, such as naked mole rats, blind mole rats, elephants, and whales, have attracted increasing attention from researchers, with the aim of characterizing the most intimate mechanisms of disease resistance in these species and breeds (1). These cancer resistance mechanisms observed in these species could offer new strategic approaches for anticancer treatments in humans, as well as in domestic and exotic animals. Therefore, by examining both tumor-prone animals closest to humans, such as dogs and cats, and tumor-resistant species, comparative oncology explores the similarities and differences between human and animal cancers, contributing to the development of new diagnostic tools, therapies, and preventive strategies that advance both human and veterinary medicine.
- Open Access
- 10 July 2025
- Published by Frontiers Media SA in Frontiers in Veterinary Science
- Vol. 12, 1570720
Enhanced sensitivity, robust p21 activation, and sustained DNA repair responses to interstrand crosslinks in elephant cells compared to humans
Elephants exhibit remarkable resistance to cancer, and understanding these mechanisms has focused on their potential applications in cancer prevention and treatment in humans. A genome-wide comparative analysis identified that the accelerated regions in elephants are enriched in Fanconi anemia (FA) complementation group L (FANCL), a ubiquitin E3 ligase that mediates the monoubiquitylation of FANCD2 as an essential step in the FA pathway. The FA pathway plays a crucial role in DNA interstrand crosslink (ICL) repair, contributing substantially to genome stability and cancer resistance. In this study, we investigated the differences in ICL repair via the FA pathway, including the function of FANCL, as well as the DNA damage response to ICLs between elephants and humans. We found that elephant fibroblasts exhibited higher sensitivity to ICL-inducing treatments, such as mitomycin C and trimethylpsoralen plus UVA (PUVA), than human fibroblasts, while showing comparable or reduced sensitivity to other DNA-damaging agents, such as doxorubicin and bleomycin. Functional analyses revealed that elephant and human FANCL performed similarly in mediating FANCD2 monoubiquitylation and cell viability following mitomycin C treatment. Interestingly, elephant fibroblasts exhibited a more potent and prolonged activation of p21 and sustained DNA repair responses, such as FANCD2 monoubiquitylation and increased RAD51expression, following ICL-induced treatments. Moreover, elephant fibroblasts showed significantly greater RAD51 foci formation than human fibroblasts after PUVA treatment, even under comparable levels of DNA damage. These findings suggest that elephants efficiently repair ICLs in growth-arrested cells likely through robust p21 activation. This study provides new insights into the cancer resistance mechanisms of elephants and offers novel approaches for cancer prevention and therapy.
- 10 July 2025
- Published by Frontiers Media SA in Frontiers in Veterinary Science
- Vol. 12, 1570720
Open AccessEnhanced sensitivity, robust p21 activation, and sustained DNA repair responses to interstrand crosslinks in elephant cells compared to humans
Elephants exhibit remarkable resistance to cancer, and understanding these mechanisms has focused on their potential applications in cancer prevention and treatment in humans. A genome-wide comparative analysis identified that the accelerated regions in elephants are enriched in Fanconi anemia (FA) complementation group L (FANCL), a ubiquitin E3 ligase that mediates the monoubiquitylation of FANCD2 as an essential step in the FA pathway. The FA pathway plays a crucial role in DNA interstrand crosslink (ICL) repair, contributing substantially to genome stability and cancer resistance. In this study, we investigated the differences in ICL repair via the FA pathway, including the function of FANCL, as well as the DNA damage response to ICLs between elephants and humans. We found that elephant fibroblasts exhibited higher sensitivity to ICL-inducing treatments, such as mitomycin C and trimethylpsoralen plus UVA (PUVA), than human fibroblasts, while showing comparable or reduced sensitivity to other DNA-damaging agents, such as doxorubicin and bleomycin. Functional analyses revealed that elephant and human FANCL performed similarly in mediating FANCD2 monoubiquitylation and cell viability following mitomycin C treatment. Interestingly, elephant fibroblasts exhibited a more potent and prolonged activation of p21 and sustained DNA repair responses, such as FANCD2 monoubiquitylation and increased RAD51expression, following ICL-induced treatments. Moreover, elephant fibroblasts showed significantly greater RAD51 foci formation than human fibroblasts after PUVA treatment, even under comparable levels of DNA damage. These findings suggest that elephants efficiently repair ICLs in growth-arrested cells likely through robust p21 activation. This study provides new insights into the cancer resistance mechanisms of elephants and offers novel approaches for cancer prevention and therapy.
- Open Access
- 4 September 2023
- Published by Sistema de Bibliotecas UACH in Austral journal of veterinary sciences
- Vol. 55  (3) , 197-202
Comparisons of beta2-microglobulin, apolipoprotein A1, and immunoglobulins (IgG and IgM) detected in the serum and urine from individual cats
Detection of serum and urinary proteins is important for normal conditions, but comparison of individual serum and urine proteins is rarely performed. The aim of this study was to examine beta2-microglobulin (beta2-MG), apolipoprotein A-I (ApoA-I), and immunoglobulins (IgG and IgM) in the serum and urine of cats with chronic kidney disease and lower urinary tract disease (LUTD), in addition to healthy cats. Serum and urine samples were analyzed using sodium dodecyl sulfate–polyacrylamide gel electrophoresis, followed by immunoblotting for beta2-MG, ApoA-I, IgG, and IgM. The molecular weight of serum beta2-MG was greater than the predicted molecular weight (11,472 Da), and different types of modified beta2-MGs were detected in the urine of healthy and diseased cats including original type in addition to grycocylated and partially digested types. Serum and urinary ApoA-I molecular weights were lower than the predicted molecular weight (28,943 Da), and high levels of urinary ApoA-I were detected in LUTD cats, although urinary ApoA-I was not detected in healthy cats. Under non-reducing conditions, H-chains of urinary IgM pentamers and IgG monomers were detected in healthy cats. These results suggest that urinary beta2-MG is modified in a different manner from serum beta2-MG, urinary ApoA-I is a potential marker of LUTD, and urinary IgM pentamer, IgG monomer, and their H-chains are found after glomerular filtration even in healthy conditions.
- 4 September 2023
- Published by Sistema de Bibliotecas UACH in Austral journal of veterinary sciences
- Vol. 55  (3) , 197-202
Open AccessComparisons of beta2-microglobulin, apolipoprotein A1, and immunoglobulins (IgG and IgM) detected in the serum and urine from individual cats
Detection of serum and urinary proteins is important for normal conditions, but comparison of individual serum and urine proteins is rarely performed. The aim of this study was to examine beta2-microglobulin (beta2-MG), apolipoprotein A-I (ApoA-I), and immunoglobulins (IgG and IgM) in the serum and urine of cats with chronic kidney disease and lower urinary tract disease (LUTD), in addition to healthy cats. Serum and urine samples were analyzed using sodium dodecyl sulfate–polyacrylamide gel electrophoresis, followed by immunoblotting for beta2-MG, ApoA-I, IgG, and IgM. The molecular weight of serum beta2-MG was greater than the predicted molecular weight (11,472 Da), and different types of modified beta2-MGs were detected in the urine of healthy and diseased cats including original type in addition to grycocylated and partially digested types. Serum and urinary ApoA-I molecular weights were lower than the predicted molecular weight (28,943 Da), and high levels of urinary ApoA-I were detected in LUTD cats, although urinary ApoA-I was not detected in healthy cats. Under non-reducing conditions, H-chains of urinary IgM pentamers and IgG monomers were detected in healthy cats. These results suggest that urinary beta2-MG is modified in a different manner from serum beta2-MG, urinary ApoA-I is a potential marker of LUTD, and urinary IgM pentamer, IgG monomer, and their H-chains are found after glomerular filtration even in healthy conditions.
- Open Access
- 10 February 2023
- Published by MDPI AG in Veterinary Sciences
- Vol. 10  (2) , 145
A Highly Conserved Region in BRCA2 Suppresses the RAD51-Interaction Activity of BRC Repeats
Mammary tumors are the most prevalent type of tumors in female dogs. Breast cancer 2, early onset (BRCA2) malignant mutations are associated with tumorigenesis in humans and dogs. BRCA2 plays a pivotal role in homologous recombination repair by recruiting RAD51 recombinase to DNA damage sites to maintain genome stability. To recruit RAD51, BRCA2 must interact with RAD51 via BRC repeats, but the regulation of this interaction has been unclear. In this study, we focused on a highly conserved region (HCR) near BRC repeats. Using co-immunoprecipitation and mammalian two-hybrid assay, we found that HCR suppressed the RAD51-interaction activity of BRC repeats and that substitutions of HCR phosphorylation sites affected it. In canine tumor samples, we found ten mutations, including a novel HCR mutation (I1110M) from canine tumor samples. The effect of four HCR mutations, including I1110M, on the RAD51-interaction activity of BRC repeats was tested. One of the HCR mutations found in canine mammary tumors increased the interaction, but the two mutations found in human breast cancers decreased it. This study suggested that the HCR regulated the RAD51-interacting activity of BRC repeats through HCR phosphorylation and that mutations in HCR may be related to tumorigenesis in both dogs and humans.
- 10 February 2023
- Published by MDPI AG in Veterinary Sciences
- Vol. 10  (2) , 145
Open AccessA Highly Conserved Region in BRCA2 Suppresses the RAD51-Interaction Activity of BRC Repeats
Mammary tumors are the most prevalent type of tumors in female dogs. Breast cancer 2, early onset (BRCA2) malignant mutations are associated with tumorigenesis in humans and dogs. BRCA2 plays a pivotal role in homologous recombination repair by recruiting RAD51 recombinase to DNA damage sites to maintain genome stability. To recruit RAD51, BRCA2 must interact with RAD51 via BRC repeats, but the regulation of this interaction has been unclear. In this study, we focused on a highly conserved region (HCR) near BRC repeats. Using co-immunoprecipitation and mammalian two-hybrid assay, we found that HCR suppressed the RAD51-interaction activity of BRC repeats and that substitutions of HCR phosphorylation sites affected it. In canine tumor samples, we found ten mutations, including a novel HCR mutation (I1110M) from canine tumor samples. The effect of four HCR mutations, including I1110M, on the RAD51-interaction activity of BRC repeats was tested. One of the HCR mutations found in canine mammary tumors increased the interaction, but the two mutations found in human breast cancers decreased it. This study suggested that the HCR regulated the RAD51-interacting activity of BRC repeats through HCR phosphorylation and that mutations in HCR may be related to tumorigenesis in both dogs and humans.
- Open Access
- 17 December 2022
- Published by MDPI AG in Veterinary Sciences
- Vol. 9  (12) , 703
Canine Mammary Tumor Cell Lines Derived from Metastatic Foci Show Increased RAD51 Expression but Diminished Radioresistance via p21 Inhibition
Due to the high incidence of mammary tumors in dogs, it is important to elucidate the pathogenesis of these tumors in veterinary medicine. Radiation therapy is often used to treat mammary tumors that target DNA lesions. RAD51 is a key molecule that repairs DNA damage via homologous recombination. We examined the relationship between RAD51 expression and radiosensitivity in mammary tumor cell lines. CHMp and CHMm from the same individual were selected based on the differences in RAD51 expression. The radiosensitivity of both cell lines was examined using MTT and scratch assays; CHMm, which has high RAD51 expression, showed higher sensitivity to radiation than CHMp. However, the nuclear focus of RAD51 during DNA repair was formed normally in CHMp, but not in most of CHMm. Since irradiation resulted in the suppression of cell cycle progression in CHMp, the expression of p21, a cell cycle regulatory factor, was detected in CHMp after 15 Gy irradiation but not in CHMm. These results indicate that functional expression is more important than the quantitative expression of RAD51 in canine mammary tumor cells in response to DNA damage.
- 17 December 2022
- Published by MDPI AG in Veterinary Sciences
- Vol. 9  (12) , 703
Open AccessCanine Mammary Tumor Cell Lines Derived from Metastatic Foci Show Increased RAD51 Expression but Diminished Radioresistance via p21 Inhibition
Due to the high incidence of mammary tumors in dogs, it is important to elucidate the pathogenesis of these tumors in veterinary medicine. Radiation therapy is often used to treat mammary tumors that target DNA lesions. RAD51 is a key molecule that repairs DNA damage via homologous recombination. We examined the relationship between RAD51 expression and radiosensitivity in mammary tumor cell lines. CHMp and CHMm from the same individual were selected based on the differences in RAD51 expression. The radiosensitivity of both cell lines was examined using MTT and scratch assays; CHMm, which has high RAD51 expression, showed higher sensitivity to radiation than CHMp. However, the nuclear focus of RAD51 during DNA repair was formed normally in CHMp, but not in most of CHMm. Since irradiation resulted in the suppression of cell cycle progression in CHMp, the expression of p21, a cell cycle regulatory factor, was detected in CHMp after 15 Gy irradiation but not in CHMm. These results indicate that functional expression is more important than the quantitative expression of RAD51 in canine mammary tumor cells in response to DNA damage.
- Open Access
- 8 July 2022
- Published by Springer Nature in Parasites & Vectors
- Vol. 15  (1) , 1-13
Plasmodium berghei Brca2 is required for normal development and differentiation in mice and mosquitoes
Background: Malaria is a major global parasitic disease caused by species of the genus Plasmodium. Zygotes of Plasmodium spp. undergo meiosis and develop into tetraploid ookinetes, which differentiate into oocysts that undergo sporogony. Homologous recombination (HR) occurs during meiosis and introduces genetic variation. However, the mechanisms of HR in Plasmodium are unclear. In humans, the recombinases DNA repair protein Rad51 homolog 1 (Rad51) and DNA meiotic recombinase 1 (Dmc1) are required for HR and are regulated by breast cancer susceptibility protein 2 (BRCA2). Most eukaryotes harbor BRCA2 homologs. Nevertheless, these have not been reported for Plasmodium. Methods: A Brca2 candidate was salvaged from a database to identify Brca2 homologs in Plasmodium. To confirm that the candidate protein was Brca2, interaction activity between Plasmodium berghei (Pb) Brca2 (PbBrca2) and Rad51 (PbRad51) was investigated using a mammalian two-hybrid assay. To elucidate the functions of PbBrca2, PbBrca2 was knocked out and parasite proliferation and differentiation were assessed in mice and mosquitoes. Transmission electron microscopy was used to identify sporogony. Results: The candidate protein was conserved among Plasmodium species, and it was indicated that it harbors critical BRCA2 domains including BRC repeats, tower, and oligonucleotide/oligosaccharide-binding-fold domains. The P. berghei BRC repeats interacted with PbRad51. Hence, the candidate was considered a Brca2 homolog. PbBrca2 knockout parasites were associated with reduced parasitemia with increased ring stage and decreased trophozoite stage counts, gametocytemia, female gametocyte ratio, oocyst number, and ookinete development in both mice and mosquitoes. Nevertheless, the morphology of the blood stages in mice and the ookinete stage was comparable to those of the wild type parasites. Transmission electron microscopy results showed that sporogony never progressed in Brca2-knockout parasites. Conclusions: Brca2 is implicated in nearly all Plasmodium life cycle stages, and especially in sporogony. PbBrca2 contributes to HR during meiosis. Graphical
- 8 July 2022
- Published by Springer Nature in Parasites & Vectors
- Vol. 15  (1) , 1-13
Open AccessPlasmodium berghei Brca2 is required for normal development and differentiation in mice and mosquitoes
Background: Malaria is a major global parasitic disease caused by species of the genus Plasmodium. Zygotes of Plasmodium spp. undergo meiosis and develop into tetraploid ookinetes, which differentiate into oocysts that undergo sporogony. Homologous recombination (HR) occurs during meiosis and introduces genetic variation. However, the mechanisms of HR in Plasmodium are unclear. In humans, the recombinases DNA repair protein Rad51 homolog 1 (Rad51) and DNA meiotic recombinase 1 (Dmc1) are required for HR and are regulated by breast cancer susceptibility protein 2 (BRCA2). Most eukaryotes harbor BRCA2 homologs. Nevertheless, these have not been reported for Plasmodium. Methods: A Brca2 candidate was salvaged from a database to identify Brca2 homologs in Plasmodium. To confirm that the candidate protein was Brca2, interaction activity between Plasmodium berghei (Pb) Brca2 (PbBrca2) and Rad51 (PbRad51) was investigated using a mammalian two-hybrid assay. To elucidate the functions of PbBrca2, PbBrca2 was knocked out and parasite proliferation and differentiation were assessed in mice and mosquitoes. Transmission electron microscopy was used to identify sporogony. Results: The candidate protein was conserved among Plasmodium species, and it was indicated that it harbors critical BRCA2 domains including BRC repeats, tower, and oligonucleotide/oligosaccharide-binding-fold domains. The P. berghei BRC repeats interacted with PbRad51. Hence, the candidate was considered a Brca2 homolog. PbBrca2 knockout parasites were associated with reduced parasitemia with increased ring stage and decreased trophozoite stage counts, gametocytemia, female gametocyte ratio, oocyst number, and ookinete development in both mice and mosquitoes. Nevertheless, the morphology of the blood stages in mice and the ookinete stage was comparable to those of the wild type parasites. Transmission electron microscopy results showed that sporogony never progressed in Brca2-knockout parasites. Conclusions: Brca2 is implicated in nearly all Plasmodium life cycle stages, and especially in sporogony. PbBrca2 contributes to HR during meiosis. Graphical
- Open Access
- 6 April 2022
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 23  (7) , 4060
BRCA2 C-Terminal RAD51-Binding Domain Confers Resistance to DNA-Damaging Agents
Breast cancer type 2 susceptibility (BRCA2) protein is crucial for initiating DNA damage repair after chemotherapy with DNA interstrand crosslinking agents or X-ray irradiation, which induces DNA double-strand breaks. BRCA2 contains a C-terminal RAD51-binding domain (CTRBD) that interacts with RAD51 oligomer-containing nucleofilaments. In this study, we investigated CTRBD expression in cells exposed to X-ray irradiation and mitomycin C treatment. Surprisingly, BRCA2 CTRBD expression in HeLa cells increased their resistance to X-ray irradiation and mitomycin C. Under endogenous BRCA2 depletion using shRNA, the sensitivities of the BRCA2-depleted cells with and without the CTRBD did not significantly differ. Thus, the resistance to X-ray irradiation conferred by an exogenous CTRBD required endogenous BRCA2 expression. BRCA2 CTRBD-expressing cells demonstrated effective RAD51 foci formation and increased homologous recombination efficiency, but not nonhomologous end-joining efficiency. To the best of our knowledge, our study is the first to report the ability of the BRCA2 functional domain to confer resistance to X-ray irradiation and mitomycin C treatment by increased homologous recombination efficiency. Thus, this peptide may be useful for protecting cells against X-ray irradiation or chemotherapeutic agents.
- 6 April 2022
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 23  (7) , 4060
Open AccessBRCA2 C-Terminal RAD51-Binding Domain Confers Resistance to DNA-Damaging Agents
Breast cancer type 2 susceptibility (BRCA2) protein is crucial for initiating DNA damage repair after chemotherapy with DNA interstrand crosslinking agents or X-ray irradiation, which induces DNA double-strand breaks. BRCA2 contains a C-terminal RAD51-binding domain (CTRBD) that interacts with RAD51 oligomer-containing nucleofilaments. In this study, we investigated CTRBD expression in cells exposed to X-ray irradiation and mitomycin C treatment. Surprisingly, BRCA2 CTRBD expression in HeLa cells increased their resistance to X-ray irradiation and mitomycin C. Under endogenous BRCA2 depletion using shRNA, the sensitivities of the BRCA2-depleted cells with and without the CTRBD did not significantly differ. Thus, the resistance to X-ray irradiation conferred by an exogenous CTRBD required endogenous BRCA2 expression. BRCA2 CTRBD-expressing cells demonstrated effective RAD51 foci formation and increased homologous recombination efficiency, but not nonhomologous end-joining efficiency. To the best of our knowledge, our study is the first to report the ability of the BRCA2 functional domain to confer resistance to X-ray irradiation and mitomycin C treatment by increased homologous recombination efficiency. Thus, this peptide may be useful for protecting cells against X-ray irradiation or chemotherapeutic agents.
- Open Access
- 4 February 2022
- Published by Springer Nature in Research Square
Plasmodium berghei Brca2 Is Required for Normal Development and Differentiation in Mice and Mosquitoes
Background: Malaria is a major global parasitic infestation caused by Plasmodium spp. Its zygotes undergo meiosis and develop into haploid ookinetes which differentiate into oocysts that undergo sporogony. Homologous recombination (HR) occurs during meiosis and introduces genetic variation. However, the mechanisms of HR in Plasmodium are unclear. In humans, the recombinases Rad51 and Dmc1 are required for HR and are regulated by BRCA2. Most eukaryotes harbor BRCA2 homologs. Nevertheless, they have not been reported for Plasmodium.Methods: A Brca2 candidate was salvaged from a database to identify Brca2 homologs in Plasmodium. To confirm that the candidate protein was Brca2, interaction activity between Plasmodium berghei (Pb) Brca2 and Rad51 was tested by a mammalian two-hybrid assay. To elucidate the functions of PbBrca2, it was knocked out and parasite proliferation and differentiation were assessed in mice and mosquitoes. Transmission electron microscopy was used to identify sporogony.Results: The candidate protein was conserved among Plasmodium species and indicated that they harbored critical BRCA2 domains including BRC repeats, tower, and oligonucleotide/oligosaccharide-binding-fold domains. The P. berghei BRC repeats interacted with PbRad51. Hence, this candidate was considered a Brca2 homolog. PbBrca2 knockout parasites were associated with reduced parasitemia, gametocytemia, female gametocyte ratio, oocyst number, and ookinete development in both mice and mosquitoes. Nevertheless, gametocyte and ookinete morphology was comparable with that of wild type parasites. Transmission electron microscopy disclosed that sporogony never progressed in Brca2-knockout parasites.Conclusions: Brca2 is implicated in nearly all Plasmodium life cycle stages and especially in sporogony. PbBrca2 contributes to homologous recombination during meiosis.
- 4 February 2022
- Published by Springer Nature in Research Square
Open AccessPlasmodium berghei Brca2 Is Required for Normal Development and Differentiation in Mice and Mosquitoes
Background: Malaria is a major global parasitic infestation caused by Plasmodium spp. Its zygotes undergo meiosis and develop into haploid ookinetes which differentiate into oocysts that undergo sporogony. Homologous recombination (HR) occurs during meiosis and introduces genetic variation. However, the mechanisms of HR in Plasmodium are unclear. In humans, the recombinases Rad51 and Dmc1 are required for HR and are regulated by BRCA2. Most eukaryotes harbor BRCA2 homologs. Nevertheless, they have not been reported for Plasmodium.Methods: A Brca2 candidate was salvaged from a database to identify Brca2 homologs in Plasmodium. To confirm that the candidate protein was Brca2, interaction activity between Plasmodium berghei (Pb) Brca2 and Rad51 was tested by a mammalian two-hybrid assay. To elucidate the functions of PbBrca2, it was knocked out and parasite proliferation and differentiation were assessed in mice and mosquitoes. Transmission electron microscopy was used to identify sporogony.Results: The candidate protein was conserved among Plasmodium species and indicated that they harbored critical BRCA2 domains including BRC repeats, tower, and oligonucleotide/oligosaccharide-binding-fold domains. The P. berghei BRC repeats interacted with PbRad51. Hence, this candidate was considered a Brca2 homolog. PbBrca2 knockout parasites were associated with reduced parasitemia, gametocytemia, female gametocyte ratio, oocyst number, and ookinete development in both mice and mosquitoes. Nevertheless, gametocyte and ookinete morphology was comparable with that of wild type parasites. Transmission electron microscopy disclosed that sporogony never progressed in Brca2-knockout parasites.Conclusions: Brca2 is implicated in nearly all Plasmodium life cycle stages and especially in sporogony. PbBrca2 contributes to homologous recombination during meiosis.
- Open Access
- 11 August 2021
- Published by Springer Nature in Research Square
BRCA2 C-terminal RAD51-binding Domain Confers Resistance to DNA-damaging Agents
Breast cancer type 2 susceptibility (BRCA2) protein is crucial for initiating DNA damage repair after chemotherapy with DNA interstrand cross-linking agents or X-ray irradiation. These treatments induce double-stranded breaks in genomic DNA. BRCA2 contains a C-terminal RAD51-binding domain (CTRBD) that interacts with RAD51-oligomer containing nucleofilaments. RAD51 nucleofilaments are essential for the homologous recombination repair of double-stranded DNA damage. In this study, we investigated the effects of expressing the CTRBD in cells exposed to X-ray irradiation and mitomycin C treatment. Surprisingly, expressing the BRCA2 CTRBD in HeLa cells increased their resistance to X-ray irradiation and mitomycin C. To determine the ability of the BRCA2 CTRBD to mediate DNA damage repair, the endogenous BRCA2 was depleted by shRNA. No significant differences were observed between the sensitivities of the BRCA2-depleted cells with or without expressing BRCA2 CTRBD. Thus, the resistance to X-ray irradiation conferred by the exogenous CTRBD required endogenous BRCA2 expression. To the best of our knowledge, our study is the first to report the ability of the BRCA2 functional domain to confer resistance to X-ray irradiation and mitomycin C treatment. This peptide may be useful in the protection of cells against X-ray irradiation or chemotherapeutic agents.
- 11 August 2021
- Published by Springer Nature in Research Square
Open AccessBRCA2 C-terminal RAD51-binding Domain Confers Resistance to DNA-damaging Agents
Breast cancer type 2 susceptibility (BRCA2) protein is crucial for initiating DNA damage repair after chemotherapy with DNA interstrand cross-linking agents or X-ray irradiation. These treatments induce double-stranded breaks in genomic DNA. BRCA2 contains a C-terminal RAD51-binding domain (CTRBD) that interacts with RAD51-oligomer containing nucleofilaments. RAD51 nucleofilaments are essential for the homologous recombination repair of double-stranded DNA damage. In this study, we investigated the effects of expressing the CTRBD in cells exposed to X-ray irradiation and mitomycin C treatment. Surprisingly, expressing the BRCA2 CTRBD in HeLa cells increased their resistance to X-ray irradiation and mitomycin C. To determine the ability of the BRCA2 CTRBD to mediate DNA damage repair, the endogenous BRCA2 was depleted by shRNA. No significant differences were observed between the sensitivities of the BRCA2-depleted cells with or without expressing BRCA2 CTRBD. Thus, the resistance to X-ray irradiation conferred by the exogenous CTRBD required endogenous BRCA2 expression. To the best of our knowledge, our study is the first to report the ability of the BRCA2 functional domain to confer resistance to X-ray irradiation and mitomycin C treatment. This peptide may be useful in the protection of cells against X-ray irradiation or chemotherapeutic agents.